INTRODUCTION
There is little published on dosage recommendations for dental sedation in older patients. The UK has an ageing population 1 and people are retaining their teeth longer; the proportion of dentate adults over the age of 65 has increased approximately four-fold from 21% in 1978 to 77% in 2009 (Fig. 1) . 2, 3 Six percent of adults aged 65-84 and 9% of those aged 85 and over suffer from extreme dental anxiety. 2 Oral surgery procedures can be moderately invasive and may indicate sedation to improve the patient experience. 4 There are, therefore, more patients who are older and more who are dentate, potentially requiring intravenous sedation to allay anxiety during dental treatment. Older patients are known to be at greater risk of morbidity and mortality when presenting for surgery, 5 so the importance of understanding the effect of sedation on the older patient cannot be underestimated.
Conscious sedation is defined by the Department of Health as; 'A technique in which the use of a drug or drugs produces a state of depression of the central nervous system (CNS) enabling treatment to be carried out, but during which verbal contact with the patient is maintained throughout Aim The aim of this study was to investigate differences in the titrated midazolam doses in older patients undergoing oral surgery procedures under intravenous sedation. Method The records of 50 patients aged 40-92 years who had undergone oral surgery procedures under intravenous sedation at Kings College Hospital between May 2008 and February 2009 were selected at random in each of the age groups: 40, 50, 60, 70 or 80+. Results The mean dose for patients over the age of 70 (2.8 mg) was 50% less than the mean dose for those under the age of 70 (5.7 mg). Conclusions Our study found a correlation between the age of the patient and the dose of midazolam required for sedation before oral surgery procedures, with, on average, older patients requiring less midazolam. A range of doses are required in any age group, but the range decreases as age increases.
Older patients are known to have altered responses to many drugs as a result of their progressive decline in systemic physiology. 8 Midazolam is water-soluble and as older patients have a decrease in total body water content this could result in a relatively higher dose being administered. Older patients also have reduced cardiac output, resulting in decreased hepatic and renal perfusion leading to slower removal of the drug from the body, hence a lower initial dose being required.
• Informs practice in the sedation of older patients for dental procedures.
• Advocates the use of a titration method for dental sedation.
• Demonstrates the need for further evidence to inform guidance on sedation of older patients. Although not in the context of oral surgery procedures, some literature has been published on conscious sedation using midazolam in older patients. Bell et al. found a significant relationship between the dose of midazolam required using titration and the age of the patient. In 800 patients only 7.2% of those aged over 70 years required more than 5 mg of midazolam, compared to 83% of patients below the age of 70 years. 9 The elimination half-life of midazolam has been found to be significantly prolonged and total clearance of the drug significantly reduced in older males compared to young males, though interestingly no significant difference was found in females. 10 Ageing increases the pharmacodynamic sensitivity to the hypnotic effects of midazolam independent of the pharmacokinetics of the patient. 11 This suggests that the changes in water content and excretion of midazolam are not the only source of the altered action of midazolam in the older patient, but that they are also more sensitive to the drug.
Older patients also have more difficulty in achieving stability on movement following conscious sedation, 12 therefore must be adequately assessed following sedation before discharge, especially considering the consequences of falls in this group of patients. Pathology can also change the manner in which midazolam affects the older patient. Pre-operative assessment of any patient is vital when providing treatment with sedation, and older patients inevitably are more likely to suffer from co-morbidities, with most older patients being ASA grade 2 or higher. 5 Medical problems in older people are most commonly cardiovascular, 5 respiratory and endocrine, with hypertension, heart failure, dysrhythmias, COPD and diabetes frequently seen. Medications for these conditions need to be considered for their possible impact on the active concentration of midazolam, as many drugs can affect the sedative and hypotensive effect of midazolam, including very commonly prescribed drugs such as betablockers, calcium channel blockers, nitrates, diuretics, ACE inhibitors and some antifungal, antiviral and antibiotic drugs. Outcome and Death (NCEPOD), 15 which states that in patients over 70 years of age:
• Maximum of 2 mg to be drawn up at any one time • Maximum dose of 2 mg (although occasionally exceeding this may be appropriate) • Single bolus dose should not be administered • Maximum dose of midazolam (mg/ kg) should be halved and given in increments, until the desired effect is achieved.
The British Society of Gastroenterology published guidelines in 2003, recommending that older patients 'are given 1 to 2 mg initially with a sensible pause to observe effect'. 16 The British National Formulary (BNF) states that midazolam should be administered by slow IV injection initially of 0.5-1 mg in elderly patients, followed by titrating if necessary in steps of 0.5-1 mg up to a maximum dose of 3.5 mg. 13 Craig and Skelly state that in those over 65 years of age 1 mg should be administered over 30 seconds, then pause for four minutes before continuing with 0.5 mg increments every two minutes if required. 17 Furthermore they say that in this older group often only 2 mg will be required for adequate sedation.
AIM
The aim of this study was to investigate differences between the titrated midazolam doses in older patients undergoing oral surgery procedures under intravenous sedation.
OBJECTIVES
To quantify the difference in dosage of intravenous midazolam between the under 70 and over 70 age groups and to make recommendations for the treatment of older patients who are undergoing intravenous dental sedation with midazolam.
METHOD
The records of 50 patients aged 40-92 years that had undergone oral surgery procedures under intravenous sedation at Kings College Hospital, Denmark Hill, London were selected at random in each of the age groups: 40, 50, 60, 70 or 80+ (this group had an upper age of 92). Information from the notes was recorded in a proforma before being transferred to a spreadsheet for analysis. The information was collected from the 'Record of oral surgery procedure' booklet and 'Medical history form' contained in the patients' case notes. This included the patient's gender, age, drug history, ASA grading, blood pressure, pulse, oxygen saturations and midazolam dose (in milligrams).
The surgical staff providing care for the patients ranged from supervised undergraduates to consultants. All midazolam used was drawn up from 10 mg in 5 ml vials of aqueous solution for injection, not 1 mg in 1 ml, as this treatment was carried out before the NPSA Rapid response report recommendations. 14 Teaching on sedation within the hospital is to titrate midazolam against patient response, starting with 2 mg initially over 30 seconds, wait two minutes, then 1 mg every 30 seconds; and in patients who are older than 65 (or have significant medical history) 1 mg initially over one minute, wait three minutes, followed by 0.5 mg every minute.
RESULTS
Of the 50 patients whose notes were reviewed 29 were female (58%) and 21 were male (42%). The age range was from 40 to 92 years, and the mean age was 60 years at the time of treatment. 
Relevant medical history and drug history
Thirty-seven patients (74%) had recorded medical problems. These were mainly cardiovascular and respiratory. Nineteen patients (38%) had hypertension, the majority of these were over 60 years old. Thirty-five patients (70%) were on medication. It was found there was an increase in the proportion of ASA 2 patients over the age of 50 (Fig. 2) .
Dose of midazolam
In each of the age groups both the mean the doses of midazolam and, more interestingly, the range of doses within that given group, decreased as age increased (Fig. 3) . The trend of decreasing mean dose was analysed using an anova comparison of means and was found to be statistically significant (p <0.001). The mean dose for patients over the age of 70 (2.8 mg) was 50% less than the mean dose for those under the age of 70 (5.7 mg).
The 2 mg NPSA recommended maximum dose was exceeded in 50% of patients over the age of 70, and 30% exceeded the BNF's maximum dose of 3.5 mg, with no significant problems relating to the sedation recorded. No adverse outcomes were recorded in any patients.
DISCUSSION
This preliminary retrospective case note review was carried out to identify trends in dose of midazolam given to patients in a wide age range of 40-92 years, thus allowing comparison of younger and older patients. Our study found a correlation between the age of the patient and the dose of midazolam required for sedation before oral surgery procedures, with, on average, older patients requiring less midazolam. These findings mirror the study by Bell et al. 9 examining midazolam sedation for patients undergoing upper gastrointestinal endoscopies. A key finding was that each successive age group required a reduced range of doses with each successive group of increasing age. This has not previously been reported in the literature. This needs further investigation, as the range of dose to be expected may be much more useful to the clinician than a single mean value for dose in a given age group, which could lead to under or over-sedation.
To achieve adequate levels of sedation some patients over the age of 70 years required doses in excess of the suggested maximum 2 mg: 15 no complications related to midazolam occurred in this group. Following the prescriptive guidelines of NCEPOD 14 and BNF 13 may, in a substantial number of patients, result in under-sedation. Our findings confirm that titrating the dose of midazolam to patient response is safe and effective in the older patient (over 70). More investigation into the dose ranges would help clinicians when administering midazolam to older patients and may be used to improve evidence-based guidelines on dosing regimens.
The NPSA also state that flumazenil administration is known to be associated with a higher mortality rate 14 and the occurrence of a critical event such as hypoxia. 18 In the patients included in our cohort flumazenil was not administered. As midazolam can be safely administered to older patients they should be able to benefit from the same quality of care that sedation can provide, and it should therefore not be withheld on account of age.
CONCLUSIONS
Although the study was small the results were clear:
• Titrating the dose of midazolam to the patient's response is safe and effective in patients over 70 years old, provided the modified technique described is used • A range of doses will be required in any age group but that the range decreases as the age increases • The trend for increasing ASA with age was confirmed: therefore a larger study is planned to allow analysis of other factors that could influence outcomes -such as weight, co-morbidities and medications. 
